Raze Therapeutics is dedicated to the discovery and development of a new class of oncology therapeutics that target fundamental metabolic pathways essential to cancer growth and survival. By selectively targeting one-carbon (1C) metabolism using its proprietary platform, Raze is developing a pipeline of 1C metabolism therapeutics across a range of solid and hematologic cancers, including genetically-defined cancers. Raze is led by an experienced management team with a proven track record for building successful biotech companies and recognized scientific leaders in metabolism and cancer biology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/14/14 | $24,000,000 | Series A |
Astellas Venture Management Atlas Venture MPM Capital MS Ventures Novartis Venture Funds Partners Innovation Fund | undisclosed |
